Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 2
1951 1
1952 1
1955 1
1956 2
1958 1
1960 2
1961 1
1963 1
1966 1
1969 1
1970 3
1971 3
1972 2
1973 2
1974 2
1975 2
1976 7
1977 6
1978 7
1979 9
1980 9
1981 11
1982 10
1983 9
1984 10
1985 11
1986 3
1987 8
1988 7
1989 18
1990 16
1991 12
1992 16
1993 14
1994 8
1995 9
1996 12
1997 9
1998 16
1999 11
2000 10
2001 18
2002 9
2003 17
2004 25
2005 29
2006 41
2007 28
2008 28
2009 24
2010 23
2011 17
2012 17
2013 30
2014 27
2015 27
2016 22
2017 30
2018 23
2019 32
2020 31
2021 46
2022 35
2023 44
2024 37

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

881 results

Results by year

Filters applied: . Clear all
Page 1
Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial.
Mann JFE, Rossing P, Bakris G, Belmar N, Bosch-Traberg H, Busch R, Charytan DM, Hadjadj S, Gillard P, Górriz JL, Idorn T, Ji L, Mahaffey KW, Perkovic V, Rasmussen S, Schmieder RE, Pratley RE, Tuttle KR. Mann JFE, et al. Among authors: busch r. Nat Med. 2024 Oct;30(10):2849-2856. doi: 10.1038/s41591-024-03133-0. Epub 2024 Jun 24. Nat Med. 2024. PMID: 38914124 Free PMC article. Clinical Trial.
The genomic landscape across 474 surgically accessible epileptogenic human brain lesions.
López-Rivera JA, Leu C, Macnee M, Khoury J, Hoffmann L, Coras R, Kobow K, Bhattarai N, Pérez-Palma E, Hamer H, Brandner S, Rössler K, Bien CG, Kalbhenn T, Pieper T, Hartlieb T, Butler E, Genovese G, Becker K, Altmüller J, Niestroj LM, Ferguson L, Busch RM, Nürnberg P, Najm I, Blümcke I, Lal D. López-Rivera JA, et al. Among authors: busch rm. Brain. 2023 Apr 19;146(4):1342-1356. doi: 10.1093/brain/awac376. Brain. 2023. PMID: 36226386 Free PMC article.
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.
Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy MS, Illmer T, Opat S, Owen CJ, Samoylova O, Kreuzer KA, Stilgenbauer S, Döhner H, Langerak AW, Ritgen M, Kneba M, Asikanius E, Humphrey K, Wenger M, Hallek M. Goede V, et al. Among authors: busch r. N Engl J Med. 2014 Mar 20;370(12):1101-10. doi: 10.1056/NEJMoa1313984. Epub 2014 Jan 8. N Engl J Med. 2014. PMID: 24401022 Free article. Clinical Trial.
Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.
Tuttle KR, Lakshmanan MC, Rayner B, Busch RS, Zimmermann AG, Woodward DB, Botros FT. Tuttle KR, et al. Among authors: busch rs. Lancet Diabetes Endocrinol. 2018 Aug;6(8):605-617. doi: 10.1016/S2213-8587(18)30104-9. Epub 2018 Jun 14. Lancet Diabetes Endocrinol. 2018. PMID: 29910024 Clinical Trial.
Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on 'Feels, Functions, Survives'. Report of a Collaborative Discussion in a Symposium with Direct Engagement from Representatives of Patients, Investigators, the National Institutes of Health, a Patient Advocacy Organization, and a Regulatory Agency.
Raghu G, Ghazipura M, Fleming TR, Aronson KI, Behr J, Brown KK, Flaherty KR, Kazerooni EA, Maher TM, Richeldi L, Lasky JA, Swigris JJ, Busch R, Garrard L, Ahn DH, Li J, Puthawala K, Rodal G, Seymour S, Weir N, Danoff SK, Ettinger N, Goldin J, Glassberg MK, Kawano-Dourado L, Khalil N, Lancaster L, Lynch DA, Mageto Y, Noth I, Shore JE, Wijsenbeek M, Brown R, Grogan D, Ivey D, Golinska P, Karimi-Shah B, Martinez FJ. Raghu G, et al. Among authors: busch r. Am J Respir Crit Care Med. 2024 Mar 15;209(6):647-669. doi: 10.1164/rccm.202312-2213SO. Am J Respir Crit Care Med. 2024. PMID: 38174955
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.
Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grünhagen U, Bergmann M, Catalano J, Zinzani PL, Caligaris-Cappio F, Seymour JF, Berrebi A, Jäger U, Cazin B, Trneny M, Westermann A, Wendtner CM, Eichhorst BF, Staib P, Bühler A, Winkler D, Zenz T, Böttcher S, Ritgen M, Mendila M, Kneba M, Döhner H, Stilgenbauer S; International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group. Hallek M, et al. Among authors: busch r. Lancet. 2010 Oct 2;376(9747):1164-74. doi: 10.1016/S0140-6736(10)61381-5. Lancet. 2010. PMID: 20888994 Clinical Trial.
First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.
Eichhorst B, Fink AM, Bahlo J, Busch R, Kovacs G, Maurer C, Lange E, Köppler H, Kiehl M, Sökler M, Schlag R, Vehling-Kaiser U, Köchling G, Plöger C, Gregor M, Plesner T, Trneny M, Fischer K, Döhner H, Kneba M, Wendtner CM, Klapper W, Kreuzer KA, Stilgenbauer S, Böttcher S, Hallek M; international group of investigators; German CLL Study Group (GCLLSG). Eichhorst B, et al. Among authors: busch r. Lancet Oncol. 2016 Jul;17(7):928-942. doi: 10.1016/S1470-2045(16)30051-1. Epub 2016 May 20. Lancet Oncol. 2016. PMID: 27216274 Clinical Trial.
DEGRO 2004 : 10. Jahreskongress der Deutschen Gesellschaft für Radioonkologie.
Wendt TG, Gademann G, Pambor C, Grießbach I, von Specht H, Martin T, Baltas D, Kurek R, Röddiger S, Tunn UW, Zamboglou N, Eich HT, Staar S, Gossmann A, Hansemann K, Semrau R, Skripnitchenko R, Diehl V, Müller RP, Sehlen S, Willich N, Rühl U, Lukas P, Dühmke E, Engel K, Tabbert E, Bolck M, Knaack S, Annweiler H, Krempien R, Hoppe H, Harms W, Daeuber S, Schorr O, Treiber M, Debus J, Alber M, Paulsen F, Birkner M, Bakai A, Belka C, Budach W, Grosser KH, Kramer R, Kober B, Reinert M, Schneider P, Hertel A, Feldmann H, Csere P, Hoinkis C, Rothe G, Zahn P, Alheit H, Cavanaugh SX, Kupelian P, Reddy C, Pollock B, Fuss M, Roeddiger S, Dannenberg T, Rogge B, Drechsler D, Herrmann T, Alberti W, Schwarz R, Graefen M, Krüll A, Rudat V, Huland H, Fehr C, Baum C, Glocker S, Nüsslin F, Heil T, Lemnitzer H, Knips M, Baumgart O, Thiem W, Kloetzer KH, Hoffmann L, Neu B, Hültenschmidt B, Sautter-Bihl ML, Micke O, Seegenschmiedt MH, Köppen D, Klautke G, Fietkau R, Schultze J, Schlichting G, Koltze H, Kimmig B, Glatzel M, Fröhlich D, Bäsecke S, Krauß A, Strauß D, Buth KJ, Böhme R, Oehler W, Bottke D, Keilholz U, Heufelder K, Wiegel T, Hinkelbein W, Rödel C, Papadopoulos T, Munnes M, Wirtz R, Sauer R, R… See abstract for full author list ➔ Wendt TG, et al. Among authors: busch r. Strahlenther Onkol. 2004 Jun;180 Suppl 1:5-87. doi: 10.1007/BF03356734. Strahlenther Onkol. 2004. PMID: 27137922 German. No abstract available.
When Can we Feed after a Gastrointestinal Bleed?
Busch RA, Collier BR, Kaspar MB. Busch RA, et al. Curr Gastroenterol Rep. 2022 Jan;24(1):18-25. doi: 10.1007/s11894-022-00839-4. Epub 2022 Feb 11. Curr Gastroenterol Rep. 2022. PMID: 35147865 Review.
881 results